Efficacy of sequential intravenous (i.v.) to oral (p.o.) moxifloxacin in hospitalized patients with community-acquired pneumonia (CAP) due to m. pneumoniae or chlamydia spp.

J. Garau, A. Torres, D. Haverstock, P. Arvis, S. Choudhri (Barcelona, Spain; West Haven, CT, United States Of America; Puteaux, France; Toronto, ON, Canada)

Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Session: Antibiotic treatment in community-acquired pneumonia
Session type: Electronic Poster Discussion
Number: 1879
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Garau, A. Torres, D. Haverstock, P. Arvis, S. Choudhri (Barcelona, Spain; West Haven, CT, United States Of America; Puteaux, France; Toronto, ON, Canada). Efficacy of sequential intravenous (i.v.) to oral (p.o.) moxifloxacin in hospitalized patients with community-acquired pneumonia (CAP) due to m. pneumoniae or chlamydia spp.. Eur Respir J 2007; 30: Suppl. 51, 1879

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis
Source: Eur Respir J 2010; 35: 858-864
Year: 2010



IV azithromycin (AZM)/ceftriaxone (CEF) followed by PO AZM vs IV levofloxacin (LEV) followed by PO LEV in treatment of hospitalized patients with community acquired pneumonia (CAP)
Source: Eur Respir J 2003; 22: Suppl. 45, 151s
Year: 2003

Impact of telithromycin (T), azithromycin (A) and cefuroxime axetil (C) on the carriage of resistant streptococcus pneumoniae (Sp) in pts with acute exacerbation of chronic bronchitis (AECB)
Source: Annual Congress 2007 - Different aspects of COPD exacerbations
Year: 2007


Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ±] clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare
Source: Eur Respir J 2002; 20: Suppl. 38, 561s
Year: 2002

Intravenous steroids in the treatment of community-acquired pneumonia (CAP)
Source: Eur Respir J 2004; 24: Suppl. 48, 50s
Year: 2004

Impact of age and gender on efficacy and safety of omadacycline (OMC) vs. moxifloxacin (MOX) in community-acquired bacterial pneumonia (CABP)
Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies
Year: 2018




The analysis of efficiency of amoxycillin/clavulanate (AC) usage at inpatients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 2s
Year: 2006

The efficiency of moxifloxacin (MOX) in community-acquired pneumonias (CAP) treatment while the initial antibacterial therapy (IAT) was inefficient
Source: Eur Respir J 2005; 26: Suppl. 49, 638s
Year: 2005

Lower overall healthcare costs with telithromycin (TEL) versus clarithromycin (CLA) in community-acquired pneumonia (CAP)
Source: Eur Respir J 2003; 22: Suppl. 45, 152s
Year: 2003

Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006

Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP)
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008

Initial intravenous antibiotic regimen in patients hospitalized for community acquired pneumonia (CAP) in France
Source: Eur Respir J 2003; 22: Suppl. 45, 151s
Year: 2003

Antibacterial activity of telithromycin (TEL) and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in the PROTEKT study 1999–2002
Source: Eur Respir J 2004; 24: Suppl. 48, 186s
Year: 2004

Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in PROTEKT years 1–5 (1999–2004)
Source: Eur Respir J 2006; 28: Suppl. 50, 350s
Year: 2006

An experience of moxifloxacin (MOX) use in therapy of nosocomial pneumonia (NP) in patients who hadn‘t risk factors to be infected by Pseudomonas aeruginosa
Source: Eur Respir J 2005; 26: Suppl. 49, 187s
Year: 2005

Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI)
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015

Clinical efficacy of arbekacin on MRSA pneumonia by intramuscularly injection
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010

LATE-BREAKING ABSTRACT: Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma
Source: International Congress 2015 – Respiratory infections: from basic science to clinical issues
Year: 2015


Efficacy and safety of oral pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg twice daily versus oral amoxicillin/clavulanate 1000/125 mg three times daily for the treatment of bacterial community-acquired pneumonia (CAP)
Source: Eur Respir J 2001; 18: Suppl. 33, 137s
Year: 2001

Effectiveness of the empirical administration of antibiotics in community acquired pneumonia (CAP)
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007